Celgene, Boston Children's Hospital in dispute over cancer drug payments


Boston Children's Hospital is seeking millions in unpaid royalties from Celgene (CELG), WSJ reports.

In a lawsuit filed last summer, the hospital claims the company violated a 2002 contract when it ceased paying royalties on Revlimid and Pomalyst — the hospital apparently helped discover their cancer fighting abilities.

The case is further complicated by the fact that the hospital sold most of its Revlimid rights to an unnamed third party for $130.5M.

In any event, an unfavorable ruling would likely cost CELG millions, as "court filings [show] Children's [believes] it is owed $3M in unpaid royalties for the first quarter alone."

From other sites
Comments (2)
  • hneumann
    , contributor
    Comments (630) | Send Message
     
    The reason for today's pullback ?
    6 Jan 2014, 12:59 PM Reply Like
  • marc heilweil
    , contributor
    Comments (177) | Send Message
     
    So far as I know the late great Dr. Judah Folkman had the insight that is the basis of anti-angiogenesis treatment to stymie growth of cancer cells. RIP
    6 Jan 2014, 07:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs